Dr. Mark Eddings

Dr. Mark Eddings

Space Market Senior Vice President

Mark Eddings serves as senior vice president of LMI’s space market, overseeing all aspects of the market’s growth, strategy, execution, and delivery. With extensive expertise in the national security space industry, Mark fosters continued market expansion while bolstering LMI’s rapid innovation in support of customer requirements.

Prior to joining LMI, Mark served as the technical director for the Space Security and Defense Program (SSDP) in the role of the primary technical advisor to the director of SSDP, where he was directly involved in shaping national space policy, requirements, and budget recommendations regarding military and commercial space security. Prior to this position, he led a team in the development of the United States Space Force (USSF) space control force designs. These force designs received formal validation from the Joint Staff Requirements Council and were presented in table-top exercises, wargames, and other forums to leaders throughout the government, including Congress and the Vice President. The force designs created by Mark and his team have resulted in over $10 billion of new capabilities and resiliency improvements to national security space systems since 2014.

Upon earning a bachelor’s in mechanical engineering and a doctorate in bioengineering from the University of Utah Mark furthered his education and experience in biotech working for the Crump Institute for Molecular Imaging at UCLA. Following his time at UCLA, Mark transitioned to government service in Los Angeles, managing studies and research and develop programs in space control and protected satellite communications. He continued his efforts as an Air Force fellow at Oak Ridge National Laboratory, where he researched advanced manufacturing and carbon-based technologies for airborne and space-based platforms.

Prior to his fellowship, Mark worked in academia and industry, publishing over 15 peer-reviewed journal articles and conference proceedings and receiving three patents related to technologies he developed at the University of Utah and UCLA. The pharmaceutical industry uses these patents and resulting technologies to create tracers for positron emission tomography screening for various cancers and to screen monoclonal antibodies for therapeutic treatments for COVID-19 and other diseases.

Related Sessions

Generative AI: Changing the Way We Approach Content Creation

Thursday, April 11, 2024

8:45 am - 9:30 am